BEAM vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 17, 2026

BEAM

41.6
AI Score
VS
MRNA Wins

MRNA

42.8
AI Score

Investment Advisor Scores

BEAM

42score
Recommendation
HOLD

MRNA

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BEAM MRNA Winner
Revenue 32.23M 534.00M MRNA
Net Income -217.00M -2.13B BEAM
Net Margin -673.3% -397.9% MRNA
Operating Income -233.77M -2.20B BEAM
ROE -20.3% -31.4% BEAM
ROA -15.7% -19.4% BEAM
Total Assets 1.39B 10.96B MRNA
Cash 219.82M 1.72B MRNA
Debt/Equity 0.09 0.09 MRNA
Current Ratio 14.57 2.29 BEAM
Free Cash Flow -199.25M -1.25B BEAM

Relative Price Performance (Last 90 Days)

BEAM 1M: -14.8% · 3M: -25.5% MRNA 1M: +125.9% · 3M: +162.9%

Current Technical Phase

BEAM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.0%), weak momentum, RSI 31

RSI (14): 31.1 · Price: $23.10

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (54.7% over 20 days), RSI 61

RSI (14): 61.3 · Price: $145.62

Fundamentals Snapshot

Metric BEAM MRNA
Market Cap
Forward P/E -4.9 -30.4
Trailing P/E
Revenue (TTM)
Revenue Growth -0.9% 0.0%
Gross Margin -1.6% -0.7%
Operating Margin -258.3% -5.6%
EPS -0.69 -7.82
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.